COMMUNIQUÉS West-GlobeNewswire

LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment

19/11/2024 - 14:30

Turner, a seasoned biotechnology executive, was formerly CEO of Carmot Therapeutics, which was acquired by Roche in 2024 for $2.7 billion LB Pharma’s lead asset, LB-102, is a patent protected blood-brain barrier- [...]

Allogene Therapeutics Announces Participation in December Investor Conferences

19/11/2024 - 14:30

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’

19/11/2024 - 14:30

Award recognizes Lisata’s data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors Annual BioTech Breakthrough Award is devoted to honoring [...]

Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons

19/11/2024 - 14:30

Research at the prestigious Semmelweis University, Budapest, Hungary has led the way in achieving government coverage in Hungary with a code for exoskeleton training that expands access to additional spinal cord injury [...]

Kairos Pharma Approved to Dual List on Upstream

19/11/2024 - 14:30

Trading to begin November 26, 2024 under ‘KAPA’ LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (KAPA) today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and [...]

Boehringer’s focus on Health Equity drives significant upgrade in Access to Medicine Index Ranking

19/11/2024 - 14:15

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has been lifted to 8th place in the 2024 Access to Medicine Index (ATMI), up from 13th in 2022. This improvement reflects the company's [...]

Iridex Comments on Changing Glaucoma Reimbursement Landscape

19/11/2024 - 14:14

MOUNTAIN VIEW, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]

Treace Announces Participation at Stifel 2024 Healthcare Conference

18/11/2024 - 22:46

PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]

Trent Renta Promoted to Chief Operating Officer at Olansky Dermatology & Aesthetics in Atlanta, Georgia

18/11/2024 - 22:44

ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics is proud to announce the promotion of Trent Renta to Chief Operating Officer (COO). Trent has been a dedicated member of the Olansky team [...]

Publication relating to transparency notifications

18/11/2024 - 22:30

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), November 18, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]

Publication relative à des notifications de transparence

18/11/2024 - 22:30

INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 18 novembre 2024 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative [...]

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual

18/11/2024 - 22:05

CHATHAM, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of [...]

OraSure to Participate in Upcoming Investor Conference

18/11/2024 - 22:05

BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment [...]

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

18/11/2024 - 22:05

Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN [...]

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

18/11/2024 - 21:20

– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P mean reduction [...]

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

18/11/2024 - 18:00

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, [...]

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »

18/11/2024 - 18:00

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day » Cette journée, organisée en collaboration avec Phage Canada et réunissant des experts [...]

Ben Austin, CFO and COO of SPR® Therapeutics, Named to Crain’s Cleveland Business 40 Under 40 List

18/11/2024 - 17:20

CLEVELAND, Nov. 18, 2024 (GLOBE NEWSWIRE) -- For over 30 years, Crain’s Cleveland Business has recognized leading professionals in the Northeast Ohio region that have been celebrated as part of the 40 Under 40 program. [...]

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

18/11/2024 - 17:15

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at [...]